Recent developments in the clinical pharmacology of classical cytotoxic chemotherapy

British Journal of Clinical Pharmacology

Volumn 62, Issue 1, 2006, Pages 27-34

  Boddy, Alan V ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Cancer; Modelling; Pharmacogenetics; Pharmacology

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CAPECITABINE; CARBON 11; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOCHROME P450; DACTINOMYCIN; DOCETAXEL; DRUG METABOLIZING ENZYME; ETOPOSIDE; FLUDARABINE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLIC ACID ANTAGONIST; GEMCITABINE; IFOSFAMIDE; IMATINIB; IRINOTECAN; MERCAPTOPURINE; METHOTREXATE; NUCLEOTIDE DERIVATIVE; PACLITAXEL; PLATINUM; TEMOZOLOMIDE; THYMIDINE; VINCRISTINE;

ANALYTIC METHOD; AREA UNDER THE CURVE; BLOOD TOXICITY; BODY FLUID; CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL LEVEL; CHRONIC MYELOID LEUKEMIA; CLINICAL PHARMACOLOGY; DNA ADDUCT; DNA CROSS LINKING; DNA DETERMINATION; DNA STRAND BREAKAGE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG INACTIVATION; DRUG LABELING; DRUG MECHANISM; DRUG METABOLISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG UPTAKE; ENZYME REGULATION; GENE CONTROL; GENE SILENCING; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; IMAGING; INDIVIDUAL BASED POPULATION MODEL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METHYLATION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHARMACOGENETICS; PHARMACOGENOMICS; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; REVIEW; SENSITIVITY AND SPECIFICITY; SOLID TUMOR; TIME OF FLIGHT MASS SPECTROMETRY; TREATMENT PLANNING; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PHARMACOGENETICS; PHARMACOLOGY, CLINICAL;

EID: 33746865548     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02714.x     Document Type: Review

References (77)

1. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748-56.
2. Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, Goodlow JL, Tan S, Wiltshaw E. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992; 10: 520-8.
3. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Ching-Hon P. Conventional compared with individualised chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998; 338: 499-505.
4. Joel SP, Ellis P, O'Byrne K, Papamichael D, Hall M, Penson R, Nicholls S, O'Donnell C, Constantinou A, Woodhull J, Nicholson M, Smith I, Talbot D, Slevin M. Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer. J Clin Oncol 1996; 14: 1903-12.
5. Cobleigh MA, Bogel CL, Tripathy D, Tobert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. Mulitnational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after cheotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-48.
6. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers C. Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-7.
7. Gelpi E. Biomedical and biochemical applications of liquid-chromatography mass-spectrometry. J Chromatogr 1995; 703: 59-80.
8. Geoghegan KF, Kelly MA. Biochemical applications of mass spectrometry in pharmaceutical drug discovery. Mass Spectrom Rev 2005; 24: 347-66.
9. Blair IA, Tilve A. Analysis of anticancer drugs and their metabolites by mass spectrometry. Curr Drug Metab 2002; 3: 463-80.
10. Guo P, Wang XM, Zhou F, Gallo JM. Determination of vincristine in mouse plasma and brain tissues by liquid chromatography-electrospray mass spectrometry. J Chromatogr B-Anal Technol Biomed Life Sci 2004; 809: 273-8.
11. Veal GJ, Cole M, Errington J, Parry A, Hale J, Pearson ADJ, Howe K, Chisholm JC, Beane C, Brennan B, Waters F, Glaser A, Hemsworth S, McDowel H, Wright Y, Pritchard-Jones K, Pinkerton R, Jenner G, Nicholson J, Elsworth AM, Boddy AV. Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group study. Clin Cancer Res 2005; 11: 5893-9.
12. Huitema ADR, Tibben MM, Kerbusch T, Kettenes-van den Bosc JJ, Rodenhuis S, Beijnen JH. High performance liquid chromatographic determination of the stabilized cyclophosphamide metabolite 4-hydroxycyclophosphamide in plasma and red blood cells. J Liquid Chromatogr Related Technol 2000; 23: 1725-44.
13. Kalhorn TF, Ren S, Howald WN, Lawrence RF, Slattery JT. Analysis of cyclophosphamide and five metabolites from human plasma using liquid chromatography-mass spectrometry and gas chromatography-nitrogen-phosphorus detection. J Chromatogr B 1999; 732: 287-98.
14. Guichard SM, Mayer I, Jodrell DI. Simultaneous determination of capecitabine and its metabolites by HPLC and mass spectrometry for preclinical and clinical studies. J Chromatogr B 2005; 826: 232-7.
15. Pang SK, Zheng NY, Felix CA, Scavuzzo J, Boston R, Blair IA. Simultaneous determination of etoposide and its catechol metabolite in the plasma of pediatric patients by liquid chromatography/tandem mass spectrometry. J Mass Spectrom 2001; 36: 771-81.
16. Oe T, Tian Y, O'Dwyer PJ, Roberts DW, Malone MD, Bailey CJ, Blair IA. A validated liquid chromatography/tandem mass spectrometry assay for cis-amminedichloro (2-methylpyridine) platinum (II) in human plasma ultrafiltrate. Anal Chem 2002; 74: 591-9.
17. Gelderblom H, Baker SD, Zhao M, Verweij J, Sparreboom A. Distribution of paclitaxel in plasma and cerebrospinal fluid. Anti-Cancer Drugs 2003; 14: 365-8.
18. Kalhorn TF, Ren AG, Slattery JT, McCune JS, Wang J. A highly sensitive high-performance liquid chromatography-mass spectrometry method for quantification of fludarabine triphosphate in leukemic cells. J Chromatogr B-Anal Technol Biomed Life Sci 2005; 820: 243-50.
19. Fan TWM, Lane AN, Higashi RM. The promise of metabolomics in cancer molecular therapeutics. Curr Opin Mol Therapeutics 2004; 6: 584-92.
20. Kolch W, Mischak H, Pitt AR. The molecular make-up of a tumour: proteomics in cancer research. Clin Sci 2005; 108: 369-83.
21. Ippolito JE, Xu J, Jain SJ, Moulder K, Mennerick S, Crowley JR, Townsend RR, Gordon JI. An integrated functional genomics and metabolomics approach for defining poor prognosis in human neuroendocrine cancers. Proc Natl Acad Sci USA 2005; 102: 9901-6.
22. Turner SM, Hellerstein MK. Emerging applications of kinetic biomarkers in preclinical and clinical drug development. Curr Opin Drug Discov Devel 2005; 8: 115-26.
23. Davies HA, Lennard L, Lilleyman JS. Variable mercaptopurine metabolism in children with leukaemia. a problem of non-compliance. BMJ 1993; 306: 1239-40.
24. Budman DR, Meropol NJ, Reigner B, Creaven PJ, Lichtman SM, Berghorn E, Behr J, Gordon RJ, Osterwalder B, Griffin T. Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine. J Clin Oncol 1998; 16: 1795-802.
25. Karlsson MO, Anehall T, Friberg LE, Henningsson A, Kloft C, Sandstrom M, Xie R. Pharmacokinetic/pharmacodynamic modelling in oncological drug development. Basic Clin Pharmacol Toxicol 2005; 96: 206-11.
26. Coustere C, Mentre F, Sommadossi J-P, Diasio RB, Steimer J-L. A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients. Cancer Chemother Pharmacol 1991; 28: 123-9.
27. Gieschke R, Reigner B, Blesch KS, Steimer JL. Population pharmacokinetic analysis of the major metabolites of capecitabine. J Pharmacokinet Pharmacodynamics 2002; 29: 25-47.
28. Klein CE, Gupta E, Reid JM, Atherton PJ, Sloan JA, Pitot HC, Ratain MJ, Kastrissios H. Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide. Clin Pharmacol Therapeutics 2002; 72: 638-47.
29. Henningsson A, Marsh S, Loos WJ, Karlsson MO, Garsa A, Mross K, Mielke S, Vigano L, Locatelli A, Verweij J, Sparreboom A, McLeod HL. Association of CYP2C8, CYP3A4, CYP3A5 and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 2005; 11: 8097-104.
30. Chatelut E, Roche H, Plusquellec Y, Peyrille F, Debiasi J, Pujol A, Canal P, Houin G. Pharmacokinetic modelling of plasma and cerebrospinal fluid methotrexate after high-dose intravenous infusion in children. J Pharm Sci 1991; 80: 730-4.
31. Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesenti E, Germani M, Poggesi I, Rocchetti M. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res 2004; 64: 1094-101.
32. Xu L, Eiseman JL, Egorin MJ, D'Argenio DZ. Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino) 17-demethoxygeldanamycin and its active metabolite in tumor-bearing mice. J Pharmacokinet Pharmacodyn 2003; 30: 185-219.
33. Gallo JM, Vicini P, Orlansky A, Li SL, Zhou F, Ma JG, Puffer S, Bookman MA, Guo P. Pharmacokinetic model-predicted anticancer drug concentrations in human tumors. Clin Cancer Res 2004; 10: 8048-58.
34. Hochhaus A, Weisser A, La Rosee P, Emig M, Muller MC, Saussele S, Reiter A, Kuhn C, Berger U, Hehlmann R, Cross NCP. Detection and quantification of residual disease in chronic myelogenous leukemia. Leukemia 2000; 14: 998-1005.
35. Radich JP, Kopecky KJ, Boldt DH, Head D, Slovak ML, Babu R, Kirk J, Lee A, Kessler P, Appelbaum F, Gehly G. Detection of Bcr-Abl fusion genes in adult acute lymphoblastic-leukemia by the polymerase chain-reaction. Leukemia 1994; 8: 1688-95.
36. McGurk CJ, McHugh PJ, Tilby MJ, Grimaldi KA, Hartley JA. Measurement of covalent drug-DNA interactions at the nucleotide level in cells at pharmacologically relevant doses. Methods Enzymol 2001; 340: 358-76.
37. Hengstler JG, Fuchs J, Oesch F. DNA strand breaks and DNA cross-links in peripheral mononuclear blood cells of ovarian cancer patients during chemotherapy with cyclophosphamide/carboplatin. Cancer Res 1992; 52: 5622-6.
38. Reed E, Ostchega Y, Steinberg SM, Yuspa SH, Young RC, Ozols RF, Poirier MC. Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients. Cancer Res 1990; 50: 2256-60.
39. Peng B, Tilby MJ, English MW, Price L, Pearson ADJ, Boddy AV, Newell DR. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy. Br J Cancer 1997; 76: 1466-73.
40. Hartley JM, Spanswick VJ, Gander M, Giacomini G, Whelan J, Souhami RL, Hartley JA. Measurement of DNA cross-linking in patients on ifosfamide therapy using the single cell gel electrophoresis (comet) assay. Clin Cancer Res 1999; 5: 507-12.
41. Buesa JM, Losa R, Fernandez A, Sierra M, Esteban E, Diaz A, Lopez-Pousa A, Fra J. Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation. Cancer 2004; 101: 2261-9.
42. Kroep JR, Giaccone G, Voorn DA, Smit EF, Beijnen JH, Rosing H, van Moorsel CJA, van Groeningen CJ, Postmus PE, Pinedo HM, Peters GJ. Gemcitabine and paclitaxel. Pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. J Clin Oncol 1999; 17: 2190-7.
43. Yamauchi T, Ueda T. A sensitive new method for clinically monitoring cytarabine concentrations at the DNA level in leukemic cells. Biochem Pharmacol 2005; 69: 1795-803.
44. Price P, Griffiths J. Tumour pharmacokinetics? - we do need to know. Lancet 1994; 343: 1174-5.
45. Macmanus MP, Hicks RJ, Matthews JP, McKenzie A, Rischin D, Salminen EK, Ball DL. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoreadiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2003; 21: 1285-92.
46. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer Therapy. N Engl J Med 2006; 354: 496-507.
47. Saleem A, Brown GD, Brady F, Aboagye EO, Osman S, Luthra SK, Ranicar ASO, Brock CS, Stevens MFG, Newlands E, Jones T, Price P. Metabolic activation of temozolomide measured in vivo using positron emission tomography. Cancer Res 2003; 63: 2409-15.
48. Wells P, Aboagye E, Gunn RN, Osman S, Boddy AV, Taylor GA, Rafi I, Hughes AN, Calvert AH, Price PM, Newell DR. 2-[C-11]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337. J Natl Cancer Inst 2003; 95: 675-82.
49. Harte RJA, Matthews JC, O'Reilly SM, Tilsley DWO, Osman S, Brown G, Luthra SJ, Brady F, Jones T, Price PM. Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L- aspartate, folinic acid, and interferon alfa. J Clin Oncol 1999; 17: 1580-8.
50. Saleem A, Yap J, Osman S, Brady F, Suttle B, Lucas SV, Jones T, Price PM, Aboagye EO. Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action. Lancet 2000; 355 (9221): 2125-31.
51. Aboagye EO, Saleem A, Cunningham VJ, Osman S, Price PM. Extraction of 5-fluorouracil by tumor and liver: a noninvasive positron emission tomography study of patients with gastrointestinal cancer. Cancer Res 2001; 61: 4937-41.
52. van Laarhoven HWM, Punt CJA, Kamm YJL, Heerschap A. Monitoring fluoropyrimidine metabolism in solid tumors with in vivo F-19 magnetic resonance spectroscopy. Crit Rev Oncol Hematol 2005; 56: 321-43.
53. Presant CA, Wolf W, Waluch V, Wiseman C, Kennedy P, Blayney D, Brechner RR. Association of intratumoral pharmacokinetics of fluorouracil with clinical-response. Lancet 1994; 343 (8907): 1184-7.
54. Findlay MPN, Leach MO, Cunningham D, Collins DJ, Payne GS, Glaholm J, Mansi JL, McCready VR. The noninvasive monitoring of low-dose, infusional 5-fluorouracil and its modulation by interferon-alpha using in-vivo F-19 magnetic-resonance spectroscopy in patients with colorectal-cancer - a pilot-study. Ann Oncol 1993; 4: 597-602.
55. Joqueviel C, Gilard V, Martino R, MaletMartino M, Niemeyer U. Urinary stability of carboxycyclophosphamide and carboxyifosfamide, two major metabolites of the anticancer drugs cyclophosphamide and ifosfamide. Cancer Chemother Pharmacol 1997; 40: 391-9.
56. Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J, Schuetz E, Lim R, Lim HL, Ong AB, Lee HS. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 2002; 20: 3683-90.
57. Petros WP, Hopkins PJ, Spruill S, Broadwater G, Vredenburgh JJ, Colvin OM, Peters WP, Jones RB, Hall J, Marks JR. Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. J Clin Oncol 2005; 23: 6117-25.
58. DeMichele A, Aplenc R, Botbyl J, Colligan T, Wray L, Klein-Cabral M, Foulkes A, Gimotty P, Glick J, Weber B, Stadtmauer E, Rebbeck TR. Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort. J Clin Oncol 2005; 23: 5552-9.
59. Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A, Gamelin E. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity. A molecular and clinical study of 75 patients. Clin Cancer Res 2004; 10: 5151-9.
60. Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P, Rogatko A, Wang H, Blanchard RL. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 2005; 11: 1226-36.
61. Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase - biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 1988; 81: 47-51.
62. Krynetshi EY, Tai HL, Yates CR, Fessing CR, Loennechen T, Schuetz JD, Relling MV, Evans WE. Genetic-polymorphism of thiopurine S-methyltransferase - clinical importance and molecular mechanisms. Pharmacogenetics 1996; 6: 279-90.
63. Jakobsen A, Nielsen JN, Gyldenkerne N, Lindeberg J. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 2005; 23: 1365-9.
64. Aplenc R, Thompson J, Han P, La M, Zhao HQ, Lange B, Rebbeck T. Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res 2005; 65: 2482-7.
65. Goetz MP, Toft D, Reid J, Ames M, Stensgard B, Safgren S, Adjei AA, Sloan J, Atherton P, Vasile V, Salazaar S, Adjei A, Croghan G, Erlichman C. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005; 23: 1078-87.
66. Farker K, Merkel U, Wedding U, Hippius M, Hoffken K, Hoffmann A. C3435T polymorphism of MDR1 gene in colorectal cancer patients and the effect on pharmacokinetics of Irinotecan. Eur J Clin Pharmacol 2005; 61: 705.
67. Plasschaert SLA, Groninger E, Boezen M, Kema I, de Vries EGE, Uges D, Veerinan AJP, Kamps WA, Vellenga E, de Graaf SS, de Bont E. Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. Clin Pharmacol Therapeut 2004; 76: 220-9.
68. Hegi ME, Diserens A, Gorlia T, Hamou M, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JEC, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
69. Luyken C, Loeser S, Blaschke B, Kohler S, Kreuzmann A, Seghrouchni S, Reifenberger G, Sabel M. Prognostic value of MGMT methylation, TP53 mutation, and MDM2, EGFR, or CDK4 amplification in malignant glioma patients treated with adjuvant temozolomide chemotherapy. Neuro-Oncology 2005; 7: 328.
70. Madhusudan S, Middleton MR. The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. Cancer Treat Rev 2005; 31: 603-17.
71. Maier S, Dahlstroem C, Haefliger C, Plum A, Piepenbrock C. Identifying DNA methylation biomarkers of cancer drug response. Am J Pharmacogenomics 2005; 5: 223-32.
72. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor xenografts by 2″-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 2000; 60: 6039-44.
73. Samlowski WE, Leachman SA, Wade M, Cassidy P, Porter-Gill P, Busby L, Wheeler R, Boucher K, Fitzpatrick F, Jones DA, Karpf AR. Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. J Clin Oncol 2005; 23: 3897-905.
74. Gianni L, Kearns C, Giani A, Capri G, Vigano L, Locatelli A, Bonadonna G, Egorin M. Nonlinear pharmacokinetic and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995; 13: 180-90.
75. Latz JE, Rusthoven JJ, Karlsson MO, Ghosh A, Johnson RD. Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol 2006; 57: 427-35.
76. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 2002; 20: 4713-21.
77. Mathijssen RHJ, Marsh S, Karlsson MO, Xie RJ, Baker SD, Verweij J, Sparreboom A, McLeod HL. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 2003; 9: 3246-53.